english.prescrire.org > Prescrire International > N°230 - October 2021

n°230

October 2021

Issue Contents
Editorial

Free  Covid-19 vaccines: glaring inequality

p.227

New Products


Bulevirtide (Hepcludex°) and chronic hepatitis D

p.229-231
No evidence of efficacy based on clinical endpoints

The Sars-CoV-2 Delta variant: how effective are covid-19 vaccines against this strain?

p.231-232

Olaparib (Lynparza°) as a replacement for chemotherapy in certain metastatic pancreatic cancers

p.233-234

Afamelanotide (Scenesse°) and erythropoietic proto­porphyria

p.234
No demonstration of a meaningful change for patients

Fidaxomicin (Dificlir°) and C. difficile infections in children and adolescents

p.235-236

INN Common stem: -cillin, -cillinam

p.236

Apalutamide (Erleada°) and metastatic hormone­sensitive prostate cancer

p.236

Belanta­mab mafodotin (Blenrep°) and multiple mye­loma

p.237

Durvalumab (Imfinzi°) for certain small cell lung cancers

p.237

Adverse Effects


Difficulties encountered on discontinuing topical corticosteroids: patients' experiences

p.238-239

Inset. Nitrosamines: risk of contamination evalu­ated for all drugs

p.240

Ranitidine: marketing authorisation suspended due to an impurity that is a probable carcinogen

p.240-241

Metopimazine and other antiemetic neuroleptics: hospitalisations for injuries

p.241

Tramadol oral drops: children still being exposed to accidental overdose

p.242

Titanium dioxide: is it carcinogenic?

p.243

Oral cortico­steroids taken for a few days: gastro­intestinal bleeding, heart failure, septicaemia

p.244

Xabans: interstitial lung disease

p.244

Reviews


Penicillin allergy

p.245-247
Look for supporting evidence

Free  Multidrug-resistant pulmonary tuberculosis and delamanid

p.248
No demonstrated clinical benefit

Outlook


Supplementary protection certificates: an industrial protection mechanism, highly profitable for drug companies

p.249-250

Intense lobbying of politicians by health product companies in the United States of America

p.250

Clinical evaluation of drugs prior to marketing authorisation is becoming more and more inadequate

p.251

Alcohol-based hand sanitisers

p.251

Masthead


Free  Masthead

p.226

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe